Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue.
Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.5M |
| Three Month Average Volume | 49.5M |
| High Low | |
| Fifty-Two Week High | 12.4526 GBX |
| Fifty-Two Week Low | 8.87 GBX |
| Fifty-Two Week High Date | 01 Aug 2024 |
| Fifty-Two Week Low Date | 27 Oct 2023 |
| Price and Volume | |
| Current Price | 11.64 GBX |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -4.40% |
| Thirteen Week Relative Price Change | 16.96% |
| Twenty-Six Week Relative Price Change | 2.09% |
| Fifty-Two Week Relative Price Change | -2.58% |
| Year-to-Date Relative Price Change | 0.00% |
| Price Change | |
| One Day Price Change | -0.56% |
| Thirteen Week Price Change | 18.27% |
| Twenty-Six Week Price Change | 11.71% |
| Five Day Price Change | -0.60% |
| Fifty-Two Week Price Change | 9.35% |
| Year-to-Date Price Change | 7.93% |
| Month-to-Date Price Change | -0.56% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 4.55064 GBX |
| Book Value Per Share (Most Recent Quarter) | 4.52731 GBX |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.97258 GBX |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.86023 GBX |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 1.18015 GBX |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 4.83399 GBX |
| Revenue Per Share (Trailing Twelve Months) | 4.91395 GBX |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 0.2941 GBX |
| Dividend Per Share (Trailing Twelve Months) | 0.28851 GBX |
| Dividend Per Share (5 Year) | 0.29365 GBX |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 0.22911 GBX |
| Excluding Extraordinary Items (Trailing Twelve Months) | 0.26561 GBX |
| Normalized (Last Fiscal Year) | 0.55144 GBX |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 0.22964 GBX |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0.26597 GBX |
| Including Extraordinary Items (Last Fiscal Year) | 0.22911 GBX |
| Including Extraordinary Items (Trailing Twelve Months) | 0.26561 GBX |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.26343 GBX |
| Cash Per Share (Most Recent Quarter) | 0.49405 GBX |
| Cash Flow Per Share (Last Fiscal Year) | 0.6882 GBX |
| Cash Flow Per Share (Trailing Twelve Months) | 0.8396 GBX |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.02352 GBX |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 1 |
| Cash Flow Revenue (Trailing Twelve Months) | 0 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 5.88% |
| Pretax Margin (Last Fiscal Year) | 5.23% |
| Pretax Margin (5 Year) | 8.18% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 70.68% |
| Gross Margin (Trailing Twelve Months) | 69.04% |
| Gross Margin (5 Year) | 71.39% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 7.55% |
| Operating Margin (Trailing Twelve Months) | 8.47% |
| Operating Margin (5 Year) | 10.25% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 4.74% |
| Net Profit Margin (Trailing Twelve Months) | 5.41% |
| Net Profit Margin (5 Year) | 8.02% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 1.42% |
| Tangible Book Value (5 Year) | -3.42% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 3.40% |
| Revenue Growth (3 Year) | 2.50% |
| Revenue Change (Trailing Twelve Months) | 5.48% |
| Revenue Per Share Growth | 2.57% |
| Revenue Growth (5 Year) | 6.76% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 4.24% |
| Total Debt (5 Year) | 16.05% |
| Dividends | |
| Dividend Growth (3 Year) | 0.71% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 24.37% |
| EPS Change (Trailing Twelve Months) | 39.86% |
| EPS Growth (3 Year) | -16.83% |
| EPS Growth (5 Year) | -16.14% |
| EBITDA | |
| EBITDA (5 Year) | -0.07% |
| EBITDA (5 Year Interim) | -1.67% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -18.91% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 12 |
| Price to Tangible Book (Most Recent Quarter) | 14 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 2.3B |
| Net Debt (Last Fiscal Year) | 2.1B |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 2 |
| Price to Sales (Trailing Twelve Months) | 2 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 44 |
| PE Normalized (Last Fiscal Year) | 21 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 35 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 65 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 25 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 44 |
| Dividends | |
| Dividend Yield (5 Year) | 2.15% |
| Dividend Yield | 2.55% |
| Current Dividend Yield | 2.48% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 44 |
| Long Term Debt to Equity (Most Recent Quarter) | 63 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 124.33% |
| Payout Ratio (Trailing Twelve Months) | 65.90% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 449 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 81 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -111,034,500 |
| Free Cash Flow (Trailing Twelve Months) | -20,533,770 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | 7 |
| Net Interest Coverage (Trailing Twelve Months) | 5 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 59 |
| Total Debt to Equity (Most Recent Quarter) | 70 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 2.64% |
| Return on Assets (Trailing Twelve Months) | 2.99% |
| Return on Assets (5 Year) | 4.10% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 5.02% |
| Return on Equity (Trailing Twelve Months) | 5.84% |
| Return on Equity (5 Year) | 7.83% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 3.29% |
| Return on Investment (Trailing Twelve Months) | 3.62% |
| Return on Investment (5 Year) | 4.99% |